evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,060 questions · 1,105 findings · 84 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 434 · 39.3%GRADE not reported 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin Diagnostic criteria: 2 studies applied the WHO 1999 criteria for 'prediabetes' (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a; Zeng 2013) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in metformin Diagnostic criteria: 2 studies applied the WHO 1999… compared with another pharmacological glucose‐lowering monotherapy (low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose Diagnostic criteria: 1 study applied the WHO 1999 criteria for prediabetes (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a) · people at increased risk for developing type 2 diabetes
1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes
1 finding from 1 review

Metformin vs diet and exercise or another antidiabetic drug

Thiazolidinediones Diagnostic criteria: 2 trials applied the WHO 1999 criteria (FPG ≥ 7.0 mmol/L and/or a 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT) (Jin 2009; Zeng 2013). No medical association recommended the cut‐off points applied in Maji ... · people at increased risk for developing type 2 diabetes

Summary of findings table for metformin showed no clear difference in thiazolidinediones Diagnostic criteria: 2 trials applied the WHO… compared with diet and exercise or another antidiabetic drug (low certainty).

1 finding from 1 review

Metformin vs diet and exercise or another antidiabetic drug

Intensive diet plus exercise · people at increased risk for developing type 2 diabetes
4 findings from 1 review
Show 1 more finding

Metformin vs diet and exercise or another antidiabetic drug

Acarbose · people at increased risk for developing type 2 diabetes
3 findings from 1 review

Metformin vs diet and exercise or another antidiabetic drug

Thiazolidinediones · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Metformin vs diet and exercise or another antidiabetic drug

Placebo or diet and exercise · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Metformin vs diet and exercise or another antidiabetic drug

Placebo or diet and exercise Description: SF‐36 to evaluate the health utility index SF‐6D (physical component summaries and mental component summaries) Minimal important difference: difference in scores between groups of at least 3% · people at increased risk for developing type 2 diabetes
1 finding from 1 review